Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)

Blood test for can­cer de­tec­tion com­pa­ny Grail rakes in $390M in lat­est round

Just over a week af­ter Third Rock-backed Thrive un­veiled ‘re­al world’ da­ta from a large study eval­u­at­ing the abil­i­ty of its blood test to sniff out ear­ly signs of can­cer in in­di­vid­u­als with no his­to­ry of the dis­ease, ri­val Grail has raised a gar­gan­tu­an $390 mil­lion in its lat­est round of fi­nanc­ing.

Grail — which was carved out of the DNA se­quenc­ing com­pa­ny Il­lu­mi­na in 2016 — has a mul­ti-can­cer de­tec­tion blood test that re­lies on DNA se­quenc­ing to as­sess methy­la­tion, an epi­ge­net­ic change across the genome to ex­pose can­cer sig­nals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.